Ixazomib: A Review in Relapsed and/or Refractory Multiple Myeloma

被引：16

作者：

Al-Salama, Zaina T. ^{[1
]}

Garnock-Jones, Karly P. ^{[1
]}

Scott, Lesley J. ^{[1
]}

机构：

[1] Private Bag 65901, Auckland 0754, New Zealand

来源：

TARGETED ONCOLOGY | 2017年 / 12卷 / 04期

关键词：

Ixazomib; Ninlaro; MLN-2238; MLN-9708; lenalidomide; Revlimid; Ladevina; dexamethasone; ORAL PROTEASOME INHIBITOR; PLUS LENALIDOMIDE-DEXAMETHASONE; PATIENTS PTS; PLACEBO-RD; SAFETY; PHARMACOKINETICS; TOURMALINE-MM1; PHASE-1; RRMM; IRD;

D O I：

10.1007/s11523-017-0504-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The oral proteasome inhibitor ixazomib (Ninlaro (R)) is approved in the USA, EU and Japan in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma (MM) who have received at least one prior therapy. In adults with relapsed and/or refractory MM who had received one to three prior therapies, progression-free survival (PFS) was significantly prolonged in patients who received the ixazomib- versus placebo-based triple therapy in the pivotal, global TOURMALINE-MM1 trial and its regional expansion (China continuation study). A significantly longer time to progression and favourable hazard ratios for PFS were observed across all prespecified subgroups, including patients with high cytogenetic risk. Overall response was achieved in a significantly higher proportion of patients receiving ixazomib- than placebo-based treatment. Ixazomib had a manageable tolerability profile in patients with MM. Ixazomib is the first orally-administered proteasome inhibitor approved for patients with MM, and in combination with lenalidomide and dexamethasone represents an important new option for use in patients with relapsed and/or refractory MM who have previously received at least one prior therapy.

引用

页码：535 / 542

页数：8

共 28 条

[1]

[Anonymous], 2017, DAT FIL

[2]

[Anonymous], 2016, NCCN Clin Pract Guidel Oncol

[3] In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells [J].

Chauhan, Dharminder ;

Tian, Ze ;

Zhou, Bin ;

Kuhn, Deborah ;

Orlowski, Robert ;

Raje, Noopur ;

Richardson, Paul ;

Anderson, Kenneth C. .

CLINICAL CANCER RESEARCH, 2011, 17 (16) :5311-5321

[4] IMWG consensus on risk stratification in multiple myeloma [J].

Chng, W. J. ;

Dispenzieri, A. ;

Chim, C-S ;

Fonseca, R. ;

Goldschmidt, H. ;

Lentzsch, S. ;

Munshi, N. ;

Palumbo, A. ;

Miguel, J. S. ;

Sonneveld, P. ;

Cavo, M. ;

Usmani, S. ;

Durie, B. G. M. ;

Avet-Loiseau, H. .

LEUKEMIA, 2014, 28 (02) :269-277

[5]

European Medicines Agency, 2016, NINL IX CAPS EU SUMM

[6]

Food and Drug Administration, 2016, CLIN PHARM BIOPH REV

[7]

Gupta N, 2017, CLIN PHARMACOL THER, V101, pS30

[8] Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling [J].

Gupta, Neeraj ;

Diderichsen, Paul M. ;

Hanley, Michael J. ;

Berg, Deborah ;

van de Velde, Helgi ;

Harvey, R. Donald ;

Venkatakrishnan, Karthik .

CLINICAL PHARMACOKINETICS, 2017, 56 (11) :1355-1368

[9] A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis [J].

Gupta, Neeraj ;

Hanley, Michael J. ;

Harvey, R. Donald ;

Badros, Ashraf ;

Lipe, Brea ;

Kukreti, Vishal ;

Berdeja, Jesus ;

Yang, Huyuan ;

Hui, Ai-Min ;

Qian, Mark ;

Zhang, Xiaoquan ;

Venkatakrishnan, Karthik ;

Chari, Ajai .

BRITISH JOURNAL OF HAEMATOLOGY, 2016, 174 (05) :748-759

[10] Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment [J].

Gupta, Neeraj ;

Hanley, Michael J. ;

Venkatakrishnan, Karthik ;

Perez, Raymond ;

Norris, Robin E. ;

Nemunaitis, John ;

Yang, Huyuan ;

Qian, Mark G. ;

Falchook, Gerald ;

Labotka, Richard ;

Fu, Siqing .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 82 (03) :728-738

← 1 2 3 →